Medical Device News MagazineA Digital Publication for the Practicing Medical Specialist, Industry Executive, and Investor

"At ASCO, we are reporting early clinical data for three therapeutic candidates highlighting the breadth of our pipeline, which lays the foundation for our next wave of precision therapy programs to tackle significant medical challenges," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "Together, these presentations reflect how we are developing differentiated, highly selective therapies against promising disease targets, and demonstrate strong execution in advancing potential treatment options for large patient populations, including HR+/HER2- breast cancer and EGFR-mutant lung cancer. The datasets represent a diversity of fundamental value drivers in our clinical portfolio, which create opportunities to substantially expand our patient impact and highlight our ambition to deliver many more transformational medicines to patients in the future."

The company updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We are excited to partner with Mersey Care NHS Foundation Trusts and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC). The application of Pangaea’s product in the context of mental health conditions is critical, for both patients and clinicians, to support preventative health and precision medicine.”

Neogap has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumor-specific T-cells.

The healthcare industry is rapidly adopting IoT technology. According to a report by MarketsandMarkets, the global market for IoT in healthcare will grow from $127.7 billion in 2023 to $289.2 billion by 2028. The majority of IoT devices used in healthcare are related to remote...

Lightning Bolt 7 is the most advanced arterial thrombectomy system on the market. The latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a single session

Shining new light on the labyrinth of human brain vessels, researchers map 22,500 vascular cells from 428 donors and six brain regions, revealing key insights for Alzheimer's disease onset and potential treatment.

Like all previous Know Labs clinical studies, this study was designed to assess the ability of the Bio-RFID sensor to non-invasively and continuously quantify blood glucose, using the Dexcom G6® continuous glucose monitor (CGM) as a proxy for the measurement of blood glucose.

Nikos Moschos, Managing Director of PD Neurotechnology, comments: “Our monitoring device is a game-changer in the fight against Parkinson’s. Studies confirm that it is effective and easy to use, and we have seen time and again how it facilitates better treatment decisions for patients based on real-world data. By providing accurate and continuous data on symptoms, together with an ecosystem to collect and present effectively, we are always aiming to help improve the management of Parkinson’s and hopefully enhance patients' quality of life.”